Regen BioPharma Inc
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. The company engages in identifying small molecules that inhibit or express NR2F6, leading to immune cell activation for oncology applications and immune cell suppression for autoimmune diseases. It also develops several products: HemaXellarate, a cellular therapeutic product derived from au… Read more
Regen BioPharma Inc (RGBP) - Total Liabilities
Latest total liabilities as of December 2025: $6.81 Million USD
Based on the latest financial reports, Regen BioPharma Inc (RGBP) has total liabilities worth $6.81 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Regen BioPharma Inc - Total Liabilities Trend (2014–2025)
This chart illustrates how Regen BioPharma Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Regen BioPharma Inc Competitors by Total Liabilities
The table below lists competitors of Regen BioPharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
WINSTAR CAPITAL BERHAD
KLSE:0336
|
Malaysia | RM160.55 Million |
|
M'BISHI UFJ FINL - Dusseldorf Stock Exchang
DU:MFZ
|
Germany | €385.89 Trillion |
|
Sanyo Special Steel Co., Ltd.
PINK:SYPLF
|
USA | $160.21 Billion |
|
Easy Technologies Inc
PINK:EMYSF
|
USA | $337.54K |
Liability Composition Analysis (2014–2025)
This chart breaks down Regen BioPharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 28.73 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Regen BioPharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Regen BioPharma Inc (2014–2025)
The table below shows the annual total liabilities of Regen BioPharma Inc from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $6.56 Million | +22.04% |
| 2024-09-30 | $5.37 Million | -1.58% |
| 2023-09-30 | $5.46 Million | -36.50% |
| 2022-09-30 | $8.60 Million | -41.52% |
| 2021-09-30 | $14.70 Million | +97.07% |
| 2020-09-30 | $7.46 Million | -32.25% |
| 2019-09-30 | $11.01 Million | +17.98% |
| 2018-09-30 | $9.33 Million | +50.60% |
| 2017-09-30 | $6.20 Million | +583.64% |
| 2016-09-30 | $906.26K | +185.31% |
| 2015-09-30 | $317.64K | +126.42% |
| 2014-09-30 | $140.29K | -- |